Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

Ditch the painkillers! While they can provide temporary relief, there are other ways to numb pain without medication. Find ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients. Suzetrigine (Journavx ...

In the second world war, the physician Henry Beecher observed that some of his soldier patients, despite being injured on the ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The FDA Approves A New, Non-Opioid Painkiller In January, the Food and Drug Administration approved a new pain medicine called Journavx (suzetrigine), made by Vertex Pharmaceuticals. It's the ...

The Best Tail For Balance | Bindi Irwin Wants Kids To Become 'Wildlife Warriors' February 27, 2025 • The bone and joint structures in mammal tails help them keep their balance. Could those ...

The U.S. Food and Drug Administration said last week it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ... for its ambitious drug pipeline that involves winning FDA approval ...

Not a moment too soon: a drug is on the market that is effective in treating pain but is not addictive. Its generic name is suzetrigine — sold under the name Journavx — and it took 25 years to develop ...